On May 31, 2020, Cytiva announced their Fast Trak process development team will use their expertise to develop a scalable downstream protein purification method for Entos Pharmaceuticals that will enable GMP-production of the Fusogenix protein component that facilitates intracellular DNA delivery.

Cytiva will work with Entos Pharmaceuticals to optimize a clinical manufacturing solution for the company’s Covigenix COVID-19 DNA vaccine candidate. Entos Pharmaceuticals develops next generation nucleic acid medicines using their Fusogenix platform, which uses a novel mechanism of action to deliver molecules, intact and unmodified, directly into the cytosol of target cells.

Cytiva’s Fast Trak process development team will use their expertise to develop a scalable downstream protein purification method that will enable GMP-production of the Fusogenix protein component that facilitates intracellular DNA delivery. By collaborating with Cytiva, Entos will have a robust purification process that will enable them to manufacture multiple vaccine candidates and begin human clinical trials.

With more than 300 years of collective industrial knowledge, the Fast Trak team helps biotech companies around the world to develop and optimize their upstream and downstream processes.

Cytiva is a 3.3 billion USD global life sciences leader with nearly 7,000 employees across 40 sites dedicated to advancing and accelerating therapeutics.